GSK Quits Trade Group BIO as Industry Faces Uncertain Political Future
GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug price negotiation program.
GSK Quits Trade Group BIO as Industry Faces Uncertain Political Future Read More »
